Cargando…

The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold

KEY CLINICAL MESSAGE: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. ABSTRACT: The common cold is one...

Descripción completa

Detalles Bibliográficos
Autores principales: Išerić, Emina, Dahl, Thomas A., Scholey, Andrew, Iversen, Jacqueline M., Verster, Joris C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359448/
https://www.ncbi.nlm.nih.gov/pubmed/37484744
http://dx.doi.org/10.1002/ccr3.7682
_version_ 1785075884465586176
author Išerić, Emina
Dahl, Thomas A.
Scholey, Andrew
Iversen, Jacqueline M.
Verster, Joris C.
author_facet Išerić, Emina
Dahl, Thomas A.
Scholey, Andrew
Iversen, Jacqueline M.
Verster, Joris C.
author_sort Išerić, Emina
collection PubMed
description KEY CLINICAL MESSAGE: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. ABSTRACT: The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials.
format Online
Article
Text
id pubmed-10359448
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103594482023-07-22 The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold Išerić, Emina Dahl, Thomas A. Scholey, Andrew Iversen, Jacqueline M. Verster, Joris C. Clin Case Rep Case Report KEY CLINICAL MESSAGE: There is no effective treatment that reduces both the severity and duration of a common cold episode. SJP − 002 (naproxen and fexofenadine) reduced symptom severity by two‐third, and the duration of the common cold episode approximately by half. ABSTRACT: The common cold is one of the most frequently experienced immune‐related complaints. At present, available treatments have limited efficacy in inhibiting symptoms associated with upper respiratory tract infection, nor do they significantly shorten the duration of common cold episodes. Four case reports are presented of individuals with a common cold. Three of them self‐administered the combination of naproxen and fexofenadine (SJP − 002). Results of one individual were compared to her spouse, who did not take SJP − 002 to treat common cold, while two other individuals took SJP − 002 and compared symptom severity with another common cold episode they experienced previously without taking SJP − 002. SJP − 002 reduced the severity of symptoms associated with upper respiratory tract infection by two‐third and reduced the duration of the common cold episode approximately by half. In conclusion, SJP − 002 reduced the severity and duration of common cold episodes. These findings warrant further investigation of SJP − 002 in double‐blind, placebo‐controlled clinical trials. John Wiley and Sons Inc. 2023-07-20 /pmc/articles/PMC10359448/ /pubmed/37484744 http://dx.doi.org/10.1002/ccr3.7682 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Išerić, Emina
Dahl, Thomas A.
Scholey, Andrew
Iversen, Jacqueline M.
Verster, Joris C.
The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_full The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_fullStr The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_full_unstemmed The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_short The efficacy of a combination of naproxen and fexofenadine (SJP − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: Four case reports of individuals with common cold
title_sort efficacy of a combination of naproxen and fexofenadine (sjp − 002) to inhibit the symptoms that are associated with viral upper respiratory tract infection: four case reports of individuals with common cold
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359448/
https://www.ncbi.nlm.nih.gov/pubmed/37484744
http://dx.doi.org/10.1002/ccr3.7682
work_keys_str_mv AT isericemina theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT dahlthomasa theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT scholeyandrew theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT iversenjacquelinem theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT versterjorisc theefficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT isericemina efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT dahlthomasa efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT scholeyandrew efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT iversenjacquelinem efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold
AT versterjorisc efficacyofacombinationofnaproxenandfexofenadinesjp002toinhibitthesymptomsthatareassociatedwithviralupperrespiratorytractinfectionfourcasereportsofindividualswithcommoncold